Most Read Articles
01 Aug 2017
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
16 Mar 2017
Probiotics have a long history of use in humans. Defined as "live organisms that confer a health benefit on the host when administered in adequate amounts", the spectrum of use of probiotics in humans ranges from foods and dietary supplements to pharmaceutical/nutraceutical products to affect general health and disease. While the genera Lactobacillus and Bifidobacterium are the two most common probiotics associated with consumer products, there exist other organisms (eg, the yeast Saccharomyces cerevisiae, some non-pathogenic strains of Escherichia coli and Bacillus species) that are used as probiotics.1–3 One of them is the probiotic strain B. clausii that has been found to be effective for the treatment of diarrhoea and antibiotic-associated gastrointestinal side effects.4–6
Stephen Padilla, 06 Dec 2016
Dengvaxia, a recombinant, live-attenuated dengue vaccine, has the potential to bring down the number of hospitalizations by 13 to 25 percent and be cost-effective in areas of moderate-to-high dengue endemicity, according to a model comparison study.
06 Nov 2017
Treatment with rifaximin appears to effectively prevent spontaneous bacterial peritonitis in patients with cirrhosis and ascites compared with systemically absorbed antibiotics and placebo, a study has found.

Postoperative anti-HBV improves survival, reduces HCC recurrence after resection

15 Aug 2017

Postoperative anti-hepatitis B virus (HBV) therapy is beneficial for patients with intermediate stage hepatocellular carcinoma (HCC) with high HBV-DNA loads, a new observational study has shown.

Investigators classified 202 HCC patients with high preoperative HBV-DNA levels into those who received postoperative anti-HBV therapy (n=118) and those who did not (n=84). Those who received anti-HBV therapy had significantly higher overall survival (p=0.019) and tumour-free survival (p=0.002) rates compared with those who did not.

The 1-, 3- and 5-year overall survival rates were 91.3, 80.9 and 66.1 percent for those who received anti-HBV therapy and 91.7, 60.7 and 52.4 percent for those who did not, respectively.

The 1-, 3- and 5-year tumour-free survival rates for the anti-HBV therapy group were 87.0, 67.0 and 62.6 percent, respectively. For those who did not receive anti-HBV therapy, the corresponding rates were 82.1, 50.0 and 42.9 percent.

Multivariate analysis showed that no postoperative anti-HBV treatment was significantly correlated with a higher risk of recurrence of HCC after resection (hazard ratio [HR], 0.882; 95 percent CI, 0.712 to 0.938; p=0.042).

Over the follow-up period, 90 cases of HCC recurrence were reported, of which 68 were liver recurrences while 22 were metastases to other organs. The most common site of recurrence was the remnant liver (95.6 percent), while the lungs, abdominal lymph nodes and bone were the common sites of metastasis.

There were 79 death events in the 5-year follow-up. The most common cause was HCC recurrence (n=50) followed by decompensated liver cirrhosis (n=16), a combination of these reasons (n=12) and cardiac failure (n=1).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Aug 2017
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
16 Mar 2017
Probiotics have a long history of use in humans. Defined as "live organisms that confer a health benefit on the host when administered in adequate amounts", the spectrum of use of probiotics in humans ranges from foods and dietary supplements to pharmaceutical/nutraceutical products to affect general health and disease. While the genera Lactobacillus and Bifidobacterium are the two most common probiotics associated with consumer products, there exist other organisms (eg, the yeast Saccharomyces cerevisiae, some non-pathogenic strains of Escherichia coli and Bacillus species) that are used as probiotics.1–3 One of them is the probiotic strain B. clausii that has been found to be effective for the treatment of diarrhoea and antibiotic-associated gastrointestinal side effects.4–6
Stephen Padilla, 06 Dec 2016
Dengvaxia, a recombinant, live-attenuated dengue vaccine, has the potential to bring down the number of hospitalizations by 13 to 25 percent and be cost-effective in areas of moderate-to-high dengue endemicity, according to a model comparison study.
06 Nov 2017
Treatment with rifaximin appears to effectively prevent spontaneous bacterial peritonitis in patients with cirrhosis and ascites compared with systemically absorbed antibiotics and placebo, a study has found.